STOCK TITAN

Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Akebia Therapeutics director Cynthia Smith received new equity awards as part of non-employee director compensation. She was granted 35,700 restricted stock units and an option for 53,600 shares of common stock at an exercise price of $1.02 per share. Both awards vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving. After the RSU grant, she directly holds 196,633 common shares.

Positive

  • None.

Negative

  • None.
Insider Smith Cynthia
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 53,600 $0.00 --
Grant/Award Common Stock 35,700 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 53,600 shares (Direct, null); Common Stock — 196,633 shares (Direct, null)
Footnotes (1)
  1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
RSU grant 35,700 units Restricted stock units granted on June 17, 2026
Stock option grant 53,600 shares Option covering common stock granted on June 17, 2026
Option exercise price $1.02 per share Conversion/exercise price for the 53,600-share option
Option expiration June 17, 2036 Scheduled expiration date of the stock option
Shares held after grant 196,633 shares Direct common stock holdings after RSU grant
restricted stock units financial
"The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Stock Incentive Plan financial
"were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan")"
Non-Employee Director Compensation Program financial
"as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program")"
Stock Option financial
"The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Akebia Therapeutics (AKBA) director Cynthia Smith receive?

Cynthia Smith received 35,700 restricted stock units and a stock option for 53,600 shares of Akebia common stock. Both awards were granted under the 2023 Stock Incentive Plan and the company’s non-employee director compensation program as part of her board compensation.

When do Cynthia Smith’s new Akebia (AKBA) RSUs and options vest?

Both the 35,700 restricted stock units and the 53,600-share stock option vest in full on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, if she remains in continuous service.

What is the exercise price and term of Cynthia Smith’s Akebia stock option?

The stock option covers 53,600 shares of common stock at an exercise price of $1.02 per share. It becomes fully exercisable on the same vesting schedule as the RSUs and is scheduled to expire on June 17, 2036, if not exercised earlier.

How many Akebia (AKBA) shares does Cynthia Smith hold after this Form 4?

Following the grant of 35,700 restricted stock units, Cynthia Smith directly holds 196,633 shares of Akebia common stock. This figure reflects her direct non-derivative holdings reported after the transaction and does not include the newly granted but unexercised stock option.

Are Cynthia Smith’s recent Akebia equity awards open-market purchases or compensation grants?

The transactions are compensation-related grants, not open-market purchases. The Form 4 describes both the restricted stock units and the stock option as awards under Akebia’s 2023 Stock Incentive Plan and Fifth Amended and Restated Non-Employee Director Compensation Program for board service.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Smith Cynthia

(Last)(First)(Middle)
C/O AKEBIA THERAPEUTICS, INC
245 FIRST STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A35,700(1)A$0.00196,633D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1.0206/17/2026A53,60006/17/2027(2)06/17/2036Common Stock53,600$0.0053,600D
Explanation of Responses:
1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s / Carolyn Rucci, attorney-in-fact for Cynthia Smith06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)